Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 476 - 500 of 10443 in total

Cholecalciferol

Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight . Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-derived form, vitamin D2 (ergocalciferol), are...
Approved
Nutraceutical
Matched Description: … additional methyl group at C24 [L5689]. ... ergocalciferol differs from cholecalciferol in that it possesses a double bond between C22 and C23 and has an …
Matched Categories: … Bone Density Conservation Agents ... Calcium-Regulating Hormones and Agents …

Azacitidine

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it...
Approved
Investigational
Matched Description: … As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and ... In January 2007, the FDA approved the intravenous administration of azacitidine. ... [A1407,A1410,A1411,A1416,A1417] In May 2004, the FDA approved the use of azacitidine administered …
Matched Categories: … Antineoplastic Agents ... Myelosuppressive Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …

rsPSMA Vaccine

Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003)....
Approved
Investigational
Matched Description: … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly …

Efmoroctocog alfa

Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It...
Approved
Investigational
Matched Description: … Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life ... It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital ... In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than …

Butaperazine

Butaperazine was approved in 1967 , and possibly discontinued in the 1980s .
Approved
Matched Description: … Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397]. …
Matched Categories: … Antipsychotic Agents ... Neurotoxic agents …

Talimogene laherparepvec

Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It was approved by the FDA in 2015 under the market name Imlygic. ... Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, …
Matched Categories: … Antineoplastic Agents ... Antineoplastic Agents, Immunological ... Antineoplastic and Immunomodulating Agents …

Sotagliflozin

Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April ... [L46616] In May 2023, sotagliflozin was approved by the FDA to reduce the risk of cardiovascular death …
Matched Categories: … Blood Glucose Lowering Agents …

Valoctocogene roxaparvovec

Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active...
Approved
Investigational
Matched Description: … It is not approved for use in the United States. ... Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that ... [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for …

Etacrynic acid

A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Matched Categories: … Ototoxic agents ... Hypotensive Agents ... Natriuretic Agents ... Nephrotoxic agents ... Hyperglycemia-Associated Agents …

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an …
Matched Categories: … Potassium-removing Agents ... Gastric Acid Lowering Agents …

Sodium aurothiomalate

Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Matched Categories: … Antirheumatic Agents ... Specific Antirheumatic Agents …

Isradipine

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity...
Approved
Investigational
Matched Categories: … Antiarrhythmic agents ... Antihypertensive Agents ... Agents causing hyperkalemia ... Hypotensive Agents ... Cardiovascular Agents …

Rifaximin

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of...
Approved
Investigational
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Gastrointestinal Agents ... Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents …

Finasteride

Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of ... [L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. ... synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an …
Matched Categories: … Urological Agents ... Genitourinary Agents ... Agents that produce hypertension ... Skin and Mucous Membrane Agents …

Ertugliflozin

Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Description: … [A31581] Ertugliflozin was first approved by the FDA in December 2017. ... [A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] …
Matched Categories: … Blood Glucose Lowering Agents …

Susoctocog alfa

Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved ... It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for …

Bromocriptine

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Categories: … Antidepressive Agents ... Dopamine Agents ... Serotonin Agents ... Hypotensive Agents ... Anti-Dyskinesia Agents …

Abaloparatide

Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids...
Approved
Investigational
Matched Description: … Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an ... [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis ... [A256778] Abaloparatide is an osteoanabolic agent that stimulates bone formation. …
Matched Categories: … Hypotensive Agents ... Bone Density Conservation Agents …

Lifitegrast

Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) …
Matched Categories: … Anti-Inflammatory Agents ... Anti-inflammatory Agents, Miscellaneous …

Potassium bicarbonate

Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered in the FDA under the section of suitable, safe and effective ingredients for...
Approved
Matched Description: … It is used in medicine as an antacid. ... It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. …
Matched Categories: … Agents causing hyperkalemia …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside ... granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an …
Matched Categories: … Anti-HIV Agents ... Antiviral Agents ... Anti-Infective Agents ... Anti-Retroviral Agents …

Aflibercept

Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. ... [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection ... for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in August …
Matched Categories: … Angiogenesis Modulating Agents ... Antineovascularisation Agents ... Ocular Vascular Disorder Agents ... Antineoplastic and Immunomodulating Agents …

Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated)

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an …

Trofinetide

Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[ ... L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive …

Evolocumab

Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line...
Approved
Matched Description: … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line ... It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still …
Matched Categories: … Hypolipidemic Agents ... Anticholesteremic Agents ... Lipid Modifying Agents ... Lipid Regulating Agents ... Lipid Modifying Agents, Plain …
Displaying drugs 476 - 500 of 10443 in total